GLYCOMIMETICS INC. news, videos and press releases
For more news please use our advanced search feature.
GLYCOMIMETICS INC. - More news...
GLYCOMIMETICS INC. - More news...
- INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. - GLYC
- GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
- GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
- GlycoMimetics Announces Its Addition to the Russell Microcap® Index
- GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
- GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference
- GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023
- GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023
- GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022
- GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023
- GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference
- GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee
- GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- Thinking about buying stock in Baudax Bio, Kala Pharmaceuticals, GlycoMimetics, Pagaya Technologies, or Transcode Therapeutics?
- GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting
- GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022
- GlycoMimetics to Participate in Two Upcoming Investor Conferences
- GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual Meeting
- GlycoMimetics to Report Third Quarter Financial Results on November 9, 2022
- GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference
- GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer
- GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022
- GlycoMimetics to Report Second Quarter Financial Results on August 3, 2022
- GlycoMimetics to Participate at Upcoming Jefferies 2022 Healthcare Conference
- GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022
- GlycoMimetics to Report First Quarter Financial Results on April 28, 2022
- GlycoMimetics to Participate at Upcoming Roth Investor Conference
